PremiumThe FlyAmylyx upgraded to Outperform from Neutral at Baird Amylyx price target raised to $12 from $8 at H.C. Wainwright Amylyx Pharmaceuticals Q3 2024 Financial Highlights PremiumCompany AnnouncementsAmylyx Pharmaceuticals Navigates Shift to Smaller Reporting Status: Impacts on Investor Relations and Stock Volatility Amylyx CFO buys $101.4K in common stock Largest borrow rate increases among liquid names PremiumThe FlyAmylyx price target lowered to $3 from $4 at Mizuho Amylyx reports Q1 EPS ($1.75), consensus (1c) Amylyx price target lowered to $3 from $4 at Baird 
